Hepion Pharmaceuticals Reports $810K Net Loss in Q1 2026, Focuses on R&D

Hepion Pharmaceuticals, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $810,791, a significant reduction from the $6.1 million loss recorded in the same period of 2025. The company has not generated any revenue during this period, consistent with its ongoing focus on research and development rather than commercialization. Total operating expenses decreased to $798,509 from $1.3 million year-over-year, primarily due to a reduction in general and administrative costs, which fell from $1.3 million to $728,509. Research and development expenses increased to $70,000, largely attributed to a licensing agreement with Cirna Diagnostics.

The company’s financial position showed a decline in total assets, which decreased to $2.7 million from $3.1 million at the end of 2025. Current liabilities rose significantly to $735,572 from $299,383, driven by increased accrued expenses and a new subscription liability of $250,000. Stockholders’ equity also fell to $1.9 million from $2.7 million, reflecting the ongoing losses and the lack of revenue generation. As of March 31, 2026, Hepion had cash reserves of $2.6 million, down from $4.6 million a year earlier.

Strategically, Hepion entered into an intellectual property license agreement with Cirna Diagnostics on February 25, 2026, which involves an upfront payment of $50,000 and potential milestone payments totaling up to $6.85 million. This agreement is part of Hepion's efforts to expand its diagnostic capabilities in liver disease. Additionally, the company announced a private placement offering on April 21, 2026, to sell 17.5 million shares of common stock at $0.04 per share, aiming to raise $700,000 to support its operations.

Operationally, the company has not reported any significant changes in customer counts or product adoption rates, as it remains focused on research and development without commercialized products. The employee headcount and geographic expansion details were not disclosed in the filing. The company continues to face challenges in securing additional funding, which is critical for its ongoing operations and development plans. Hepion has indicated that it may need to curtail operations if it cannot raise sufficient capital.

Looking ahead, Hepion Pharmaceuticals acknowledges substantial doubt about its ability to continue as a going concern without additional capital. The company expects to incur significant losses in the foreseeable future as it continues to invest in research and development. Management has emphasized the need for additional financing to support its strategic initiatives and operational needs, highlighting the uncertainty surrounding future revenue generation and the potential impact on its financial stability.